CEL-SCI REPORTS CEL-1000 DATA

Cel-Sci has announced that its CEL-1000 peptide showed adjuvant activity when used with a peptide based malaria vaccine and a DNA-based malaria vaccine in animal challenge studies as part of a cooperative research arrangement with the Naval Medical Research Center in Silver Spring, Md. In both cases, the one-time addition of the patent protected CEL-1000 to the vaccines resulted in significant increases in the protection of the animals.

This new data indicates that CEL-1000 has protective activity in various animal models. These results are very important because the company is planning to develop CEL-1000 as a potential addition to the different bird flu vaccines currently under development by the pharmaceutical and biopharmaceutical industry. It recently became very apparent that there is a great need for an adjuvant for these vaccines. Adjuvants are designed to improve the effectiveness of vaccines.